Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-inflammatory function of Alzheimer’s disease drugs revealed

29.07.2005


Points way to development of more efficient treatment



The mechanism in anti-Alzheimer’s disease drugs that inhibits the production of a destructive, inflammation-causing protein in the brain has been revealed by researchers at the Hebrew university of Jerusalem.

Their work, described in a recent issue of the American journal, Annals of Neurology, is likely to lead to the development of more efficient drugs than are currently in use for treating Alzheimer’s Disease as well as other neurological conditions resulting from infections, autoimmune diseases such as multiple sclerosis, or brain inflammation resulting from trauma or stroke.


The research team working on this project was headed by Prof. Raz Yirmiya of the Psychology Department at the Hebrew University, Dr. Yehuda Pollak, a post-doctoral fellow in Prof. Yirmiya’s laboratory; and in cooperation with Hermona Soreq, the Charlotte Slesinger Professor of Cancer Studies at the Silberman Institute of Life Sciences at the Hebrew University, and Prof. Tamir Ben-Hur of the Hebrew University Faculty of Medicine.

Alzheimer’s Disease is a degenerative disease of the brain, characterized by a deterioration of both cognitive and physical abilities. It first affects memory and the ability to carry out complex, coordinated tasks. It also can bring on depression, inattention and outbursts of anger. In a more progressive stage, the disease can cause difficulties in the ability to perform even simple tasks such as speaking and comprehending, eating and sleeping. The affected person can even forget his name and identity.

The medicines administered today to Alzheimer’s Disease patients focus on preventing the breakdown of acetylcholine, a chemical produced by brain cells which transmits information within the brain and is vitally involved in cognitive processes that include memory, attention and thought. Because acetylcholine-producing cells are among the first to die in Alzheimer’s Disease patients, drug-induced elevation of acetylcholine levels partially attenuates the cognitive deterioration.

In recent years it has been shown that another pathological process that occurs in the brain of Alzheimer’s Disease patients is excessive immune activation and inflammation, which are induced by overproduction of an inflammation-producing protein called interleukin-1, as well as a few other related compounds. This process can impair the functioning of nerve cells and can even lead to their death. Furthermore, genetic alterations in the interleukin-1 gene have been associated with increased risk for the appearance and severity of Alzheimer’s Disease symptoms.

The Hebrew University researchers found that anti-Alzheimer’s Disease drugs currently in use not only block the activity of the enzyme responsible for breaking down acetylcholine but also cause a marked reduction in the production of interleukin-1. Furthermore, they describe the use of a novel drug (EN101), developed by Prof. Soreq’s team, which produces these effects in a more efficient way than known heretofore by destroying the molecular antecedent (messenger RNA) of the enzyme, rather than simply blocking the enzyme’s activity.

In a series of experiments, conventional anti-Alzheimer’s Disease drugs, as well as the novel drug EN101, were injected into mice with brain inflammation. It was found that these injections reduced significantly the activity of the enzyme that breaks down acetylcholine and blocked almost entirely the production of interleukin-1.

"These findings suggest a new role for acetylcholine in the brain," said Prof. Yirmiya. "When the anti-Alzheimer’s Disease drugs block the enzyme which breaks down acetylcholine, the level of this chemical in the brain goes up, and there is a reduction of the production of the inflammatory material, interleukin-1, and its destructive influence in the brain."

"The discovery of this mechanism in the anti-Alzheimer’s Disease medicines points the way towards development of new forms of these medicines which will block even more efficiently and specifically the inflammatory and destructive activity of inteleukin-1," Prof. Yirmiya stressed. "Beyond that, it is likely that the drugs that are currently used for treatment of Alzheimer’s Disease, and particularly the new drug EN101, will also be effective in dealing with other inflammatory illnesses."

Jerry Barach | EurekAlert!
Further information:
http://www.huji.ac.il

More articles from Life Sciences:

nachricht Fine organic particles in the atmosphere are more often solid glass beads than liquid oil droplets
21.04.2017 | Max-Planck-Institut für Chemie

nachricht Study overturns seminal research about the developing nervous system
21.04.2017 | University of California - Los Angeles Health Sciences

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>